ODACon™ Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies - Antibody-Drug Conjugates

ODACon™ Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies - Antibody-Drug Conjugates is organized by i3 Health and will be held from Dec 07, 2022 - Dec 06, 2023.,Statement of Need:,Breast cancer is the most common cancer diagnosed in women, with an estimated 15% of cases being human epidermal growth factor receptor 2 (HER2)–positive and 12% being triple-negative (ACS, 2019). Antibody-drug conjugates have revolutionized the treatment of HER2-positive, triple-negative, and, most recently, HER2-low unresectable or metastatic breast cancer. These drugs combine a tumor antigen–targeted monoclonal antibody with a cytotoxic payload to permit the selective delivery of the chemotherapeutic agent to cells expressing the targeted antigen (Corti et al, 2021). With the recent approval of trastuzumab deruxtecan for HER2-low breast cancer, the number of patients who may benefit from antibody-drug conjugate therapy has expanded into populations with HER2 expression too low to be considered HER2-positive (Modi et al, 2022). In this session, Julie LaBarbera, NP, will discuss the increasing use of antibody-drug conjugates in breast cancer, including the approval of sacituzumab govitecan and the expanded approval of trastuzumab deruxtecan for HER2-low breast cancer, as well as monitoring for and managing the unique side effects of these highly efficacious treatments.,Learning Objectives:,Upon completion of this activity, participants should be able to,In this session, Julia A. LaBarbera, MSN, RN, AGACNP-BC, Nurse Practitioner in Hematology/Oncology at UCLA Health in Santa Monica, California, will discuss the increasing use of antibody-drug conjugates in breast cancer, including the approval of sacituzumab govitecan and the expanded approval of trastuzumab deruxtecan for HER2-low breast cancer, as well as monitoring for and managing the unique side effects of these highly efficacious treatments.